Adams Respiratory Therapeutics Announces Two Key Additions to Its Senior Management Team

CHESTER, N.J., Oct. 29 /PRNewswire/ -- Adams Respiratory Therapeutics, a provider of specialty pharmaceuticals for respiratory care, today announced the appointment of two new members to its senior management team. Helmut Albrecht, MD has joined the company as Senior Vice President, Research and Development. Reporting to Dr. Albrecht and also new to Adams will be Susan Witham who will serve as Vice President of Regulatory Affairs.

Dr. Albrecht will oversee all research and development functions including clinical development and regulatory issues as well as new product development. Witham is responsible for regulatory affairs for the entire organization.

Helmut Albrecht Brings Breadth of Regulatory and R&D Experience

Helmut Albrecht joins Adams Respiratory Therapeutics with broad US and global experience in clinical program development and regulatory negotiation. Most recently, he served as Vice President, Global PreClinical & Clinical Development and Drug Safety at Novartis Consumer Health, OTC Business Unit. His primary responsibilities included strategy, leadership and execution of all preclinical and clinical programs in the US and globally. Prior to that, Albrecht served as Vice President for R&D OTC, NA with responsibility for regulatory, medical, clinical, technical development, R&D QA and project management as well as new technology development in North America.

Before joining Novartis, Helmut had leadership positions in the area of pharmaceutical medicine involving Rx and OTC drugs as well as dietary supplements at SmithKline Beecham, Procter & Gamble and Altana.

"The company is ready to expand its presence in the respiratory category, and I am looking forward to contributing to that growth in the R&D area," commented Dr. Albrecht.

Dr. Albrecht earned his MD degree in Germany at the Universities of Heidelberg and Hamburg. He holds a Diploma in Pharmaceutical Medicine and is a Fellow (FFPM) of the Faculty of Pharmaceutical Medicine.

Susan Witham Adds Strong Global Regulatory Experience

Before joining Adams Respiratory Therapeutics, Susan has amassed over 20 years of experience in the pharmaceutical industry, 14 years in Regulatory Affairs. Susan Witham was Vice President of Regulatory Affairs at Columbia Laboratories, Inc. where her responsibilities included submission of regulatory dossiers both globally and in the US. Previously, she served as Global Regulatory Head for Marketed Products and Practices in the Oncology and Metabolism Category at Aventis Pharmaceuticals Corporation. In this position, she managed marketing and regulatory submission for several products in the EU and US.

Susan Witham's experience in the pharmaceutical industry is extensive. She has also held senior positions in regulatory affairs for Johnson & Johnson Consumer Products Worldwide/Ortho Dermatological Drug Products, Novartis Pharmaceuticals Corporation and Sandoz Pharmaceuticals Corporation.

ABOUT Adams Respiratory Therapeutics:

Based in Chester, New Jersey, Adams Respiratory Therapeutics develops, markets and sells prescription and non-prescription pharmaceuticals for the treatment of respiratory disorders and diseases. In addition to the Mucinex(R) line of products, the Adams product portfolio includes AlleRx(TM) for the prescription treatment of allergic rhinitis. Adams seeks to become the leading specialty provider of pharmaceuticals for the treatment of a broad range of respiratory diseases via a business development strategy that combines product development, acquisitions and in-licensing tactics. More information can be found on the company's website at

Contact: Walt Riehemann Adams Respiratory Therapeutics (908) 879-1410 Margy Meislin Weber Shandwick (212) 445-8261

Adams Respiratory Therapeutics

CONTACT: Walt Riehemann of Adams Respiratory Therapeutics,+1-908-879-1410, or; or Margy Meislin of WeberShandwick, +1-212-445-8261, or, for AdamsRespiratory Therapeutics

Back to news